Summary Hims expects $2.3-2.4 billion in revenue for 2025, with $725 million from weight loss The decision to continue compounding semaglutide (GLP-1s) is controversial given the FDA has declared the shortage over Hims is likely operating within the law and should be able to defend itself against potential FDA actions and third-party litigation On February 24, 2025, Hims & Hers Health, Inc
Expression of the gene encoding the ghrelin receptor in rats selected for differential alcohol preference
Focusing on antidiabetic drugs and agents targeting specific metabolic receptors presents a promising approach to reducing both the incidence and severity of HCC (Table 4)
Several questions remain unsolved, including the connection between melanocyte depletion and stem cell exhaustion, the underlying degenerative mechanisms and the biological mediators of cell death
Patients on tirzepatide experienced greater weight loss than those on liraglutide, dulaglutide, oral semaglutide, and all but the highest dose of injectable semaglutide
Formulation, format and flavour all matter